Citadel Advisors
OCUL icon

Citadel Advisors’s Ocular Therapeutix OCUL Stock Holding History

Citadel Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$796K Buy
94,000
+10,100
+12% +$96.3K ﹤0.01% 8198
2025
Q4 		$1.02M Buy
83,900
+44,400
+112% +$539K ﹤0.01% 7358
2025
Q3 		$462K Sell
39,500
-14,100
-26% -$169K ﹤0.01% 9330
2025
Q2 		$497K Sell
53,600
-7,900
-13% -$61.8K ﹤0.01% 8650
2025
Q1 		$451K Sell
61,500
-38,200
-38% -$294K ﹤0.01% 8702
2024
Q4 		$851K Sell
99,700
-200
-0.2% -$1.95K ﹤0.01% 7390
2024
Q3 		$869K Sell
99,900
-31,100
-24% -$256K ﹤0.01% 7142
2024
Q2 		$896K Sell
131,000
-50,800
-28% -$314K ﹤0.01% 6813
2024
Q1 		$1.65M Buy
181,800
+131,700
+263% +$935K ﹤0.01% 5895
2023
Q4 		$223K Buy
50,100
+22,100
+79% +$65.4K ﹤0.01% 9720
2023
Q3 		$87.9K Sell
28,000
-142,200
-84% -$582K ﹤0.01% 11052
2023
Q2 		$878K Buy
170,200
+51,100
+43% +$304K ﹤0.01% 6732
2023
Q1 		$628K Buy
119,100
+69,200
+139% +$329K ﹤0.01% 7833
2022
Q4 		$140K Buy
49,900
+20,600
+70% +$68.2K ﹤0.01% 10716
2022
Q3 		$122K Buy
+29,300
New +$148K ﹤0.01% 10922
2022
Q1 		– Sell
-23,300
Closed -$162K – 14285
2021
Q4 		$162K Sell
23,300
-22,100
-49% -$172K ﹤0.01% 12168
2021
Q3 		$454K Sell
45,400
-9,400
-17% -$106K ﹤0.01% 10113
2021
Q2 		$777K Sell
54,800
-13,000
-19% -$198K ﹤0.01% 9018
2021
Q1 		$1.11M Sell
67,800
-1,700
-2% -$32.7K ﹤0.01% 7845
2020
Q4 		$1.44M Buy
69,500
+37,100
+115% +$551K ﹤0.01% 6032
2020
Q3 		$247K Buy
32,400
+7,700
+31% +$63.9K ﹤0.01% 8460
2020
Q2 		$206K Buy
24,700
+4,600
+23% +$30.5K ﹤0.01% 8487
2020
Q1 		$99K Buy
20,100
+5,300
+36% +$26.2K ﹤0.01% 8640
2019
Q4 		$58K Sell
14,800
-8,300
-36% -$28.9K ﹤0.01% 8715
2019
Q3 		$70K Buy
23,100
+1,300
+6% +$5.81K ﹤0.01% 8614
2019
Q2 		$96K Buy
21,800
+3,700
+20% +$13.7K ﹤0.01% 8544
2019
Q1 		$72K Sell
18,100
-500
-3% -$2.01K ﹤0.01% 8673
2018
Q4 		$74K Buy
18,600
+8,200
+79% +$45.2K ﹤0.01% 8376
2018
Q3 		$72K Buy
+10,400
New +$65.3K ﹤0.01% 8700
2017
Q3 		– Sell
-11,000
Closed -$102K – 7874
2017
Q2 		$102K Sell
11,000
-4,400
-29% -$42.6K ﹤0.01% 6900
2017
Q1 		$143K Buy
+15,400
New +$128K ﹤0.01% 6715
2016
Q4 		– Sell
-10,600
Closed -$73K – 7661
2016
Q3 		$73K Buy
+10,600
New +$64.6K ﹤0.01% 6757
2016
Q1 		– Sell
-1,400
Closed -$13K – 7607
2015
Q4 		$13K Buy
+1,400
New +$15.1K ﹤0.01% 8173

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors's OCUL Position: Q1 2026 in Review

Citadel Advisors reduced its Ocular Therapeutix (OCUL) stake by 74% in Q1 2026, selling an estimated $17.5M and leaving 635,922 shares worth $5.39M. The position accounts for ﹤0.01% of the portfolio, ranked #4230.

Citadel Advisors first reported a position in OCUL in Q2 2015 and has held it in 36 quarters since. The position peaked at $66.7M in Q3 2025. 269 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Citadel Advisors held 635,922 shares of Ocular Therapeutix worth $5.39M as of Q1 2026.
  • Citadel Advisors sold 1,839,927 Ocular Therapeutix shares in Q1 2026, an estimated $17.5M.
  • Ocular Therapeutix made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4230 holding.
  • Citadel Advisors first reported a position in Ocular Therapeutix in Q2 2015 and has held it in 36 quarters since.
  • Citadel Advisors's Ocular Therapeutix position peaked at $66.7M in Q3 2025.
  • 269 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.